Apexian Pharmaceuticals

Apexian Pharmaceuticals is an emerging clinical biotechnology company built on the scientific discoveries of Dr. Mark R. Kelley. His groundbreaking work on the APE1/Ref-1 redox signaling pathway at the Indiana University School of Medicine has provided unique insights into this important biological target. Research by Dr. Kelley, along with studies from scientists worldwide, has shown that inhibitors of APE1/Ref-1 redox signaling can impact many transcription factors involved in cancer cell signaling and survival.